Board of Directors
Drew Senyei, M.D. Enterprise Partners
Andrew E. Senyei, M.D., has served on our board of directors as chairman of the board since April 2000. Dr. Senyei has been a managing director and a general partner of Enterprise Partners, a venture capital firm, since 1987. Dr. Senyei was a founder of Molecular Biosystems, a publicly-traded biotechnology company acquired in 2000, and, prior to joining Enterprise Partners, was a practicing clinician and adjunct associate professor of obstetrics and gynecology at the University of California, Irvine. He serves on the boards of directors of numerous private healthcare companies. Dr. Senyei obtained his M.D. from Northwestern University and residency training at the University of California, Irvine, Medical Center.
Michael Henos Alliance Technology Ventures
Michael A. Henos has served on our board of directors since 2001. From 1993 to the present, Mr. Henos has served as managing general partner of Alliance Technology Ventures, L.P., based in Atlanta, Georgia. Mr. Henos served as a general partner of Aspen Ventures, an early-stage venture capital partnership, from 1991 to 2001. Mr. Henos previously served as a vice president of 3i Ventures Corporation, the predecessor of Aspen Ventures, from 1986 to 1991. From 1984 to 1986, Mr. Henos served as a healthcare consultant with Ernst & Young, specializing in venture financing of startup medical technology companies. Before joining Ernst & Young, Mr. Henos served in a variety of operating management positions and co-founded and served as chief executive officer of ProMed Technologies, Inc. Mr. Henos is the chairman of the board of directors of Inhibitex, Inc., a publicly-held clinical-stage biopharmaceutical company, and from 1994 until June 2009 was a member of the board of directors of AtheroGenics, Inc., a publicly-held biopharmaceutical company. Mr. Henos received his B.S. and M.B.A. from the University of California, Los Angeles.
Robert E. Curry, Ph.D. Alliance Technology Ventures
Robert E. Curry, Ph.D. has served on our board of directors since February 2002. Since July 2002, Dr. Curry has served as a venture partner at Alliance Technology Ventures, L.P., based in Atlanta, Georgia. From July 2001 to July 2002, Dr. Curry was engaged as a consultant to DLJ Capital Corporation, a wholly-owned subsidiary of Credit Suisse First Boston (USA), Inc., or CSFB. He joined the Sprout Group, or Sprout, a submanager of various venture capital funds within the CSFB organization, as a general partner in May 1991. Prior to joining Sprout, Dr. Curry served in various capacities with Merrill Lynch R&D Management and Merrill Lynch Venture Capital from 1984, including as president of both organizations from January 1990 to May 1991. Previously, Dr. Curry was a vice president of Becton, Dickinson and Company, a medical technology company, from May 1980 to July 1984, and general manager of the Diagnostics Systems Division of Bio-Rad Laboratories Inc., a clinical diagnostic and life sciences research company, from August 1976 to May 1980. He currently is a director of numerous privately-held companies as well as the chairman of the board and a trustee of Keck Graduate Institute, a not-for-profit organization. He is also currently the chief executive officer of SensysMedical, Inc. Dr. Curry received a B.S. from the University of Illinois, and a M.S. and Ph.D. in chemistry from Purdue University.
Laurence R. McCarthy, Ph.D. Ampersand Ventures
Laurence R. McCarthy, Ph.D. has served on our board of directors since August 2008. Dr. McCarthy has served as a venture partner with Ampersand Ventures, a private equity fund focused on healthcare investment, since 2007 and president of Scientific Technologies and Solutions, LLC, a diagnostic and technology consulting company, since 2007. From 1987 to 2006 Dr. McCarthy was president, CEO, chairman, and CTO of Focus Diagnostics and later served as its CTO following the company’s acquisition by Quest Diagnostics in 2006. Prior to this, Dr. McCarthy was president for the U.S. Diagnostics Division of Boehringer Mannheim; vice president and general manager and vice president R&D for Becton Dickinson & Co. Dr. McCarthy’s academic experience includes faculty positions at Johns Hopkins School of Medicine, University of North Carolina School of Medicine, and Cornell University School of Medicine, as well as serving as a laboratory director at the Memorial Sloan-Kettering Cancer Center and at North Carolina Memorial Hospital. Dr. McCarthy received his Ph.D. in microbiology from the University of New Hampshire and his B.S. in biology from St. Anselm College.
Karin Eastham
Karin Eastham has served on our board of directors since August 2008. Ms. Eastham serves on several life sciences boards and also provides some consulting and executive coaching to healthcare companies. From May 2004 to September 2008 she served as executive vice president and chief operating officer and as a member of the board of trustees of Burnham Institute for Medical Research, a non-profit corporation engaged in biomedical research. From April 1999 to May 2004, Ms. Eastham served as senior vice president, finance, chief financial officer and secretary of Diversa Corporation. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including vice president, finance, at Boehringer Mannheim Corporation, from 1976 to 1988. Ms. Eastham also serves as a director for Amylin, Inc., Illumina, Inc. and Geron Corporation. From August 2005 until August 2008, Ms. Eastham was a member of the board of directors of SGX Pharmaceuticals, Inc. and from December 2003 until October 2008, Ms. Eastham was a member of the board of directors of Tercica, Inc. She received a B.S. and an M.B.A. from Indiana University. She is a certified public accountant and a certified director.
Tina S. Nova, Ph.D. President, Chief Executive Officer, and Co-founder
Tina S. Nova, Ph.D., has served as our president and chief executive officer, and a member of our board of directors, since March 2000. From 1994 to January 2000, Dr. Nova served as chief operating officer and president of Nanogen, Inc., a provider of molecular diagnostic tests, where she was a co-founder. From 1992 to 1994, Dr. Nova served as chief operating officer of Selective Genetics, a targeted therapy biotechnology company. She currently serves as a member of the board of directors of Arena Pharmaceuticals, Inc. and Cypress Bioscience, Inc., both publicly held clinical-stage biopharmaceutical companies. She also serves on the board of trustees of the University of San Diego and was a former life science sector representative to the Independent Citizen’s Oversight Committee overseeing the California Stem Cell Initiative (Proposition 71). Dr. Nova holds a B.S. degree in Biological Sciences from the University of California, Irvine and a Ph.D. in Biochemistry from the University of California, Riverside.
Christine A. White, M.D.
Christine A. White, M.D., became a member of the board of directors in January 2009. Dr. White was with Biogen Idec Inc., a biopharmaceutical company, from 1996 to 2005, where she held several senior positions, most recently as senior vice president, global medical affairs. From 1994 to 1996, Dr. White served as the director of clinical oncology research at the Sidney Kimmel Cancer Center in San Diego and from 1984 to 1994, Dr. White was on the clinical staff and held various positions in the Department of Medicine at Scripps Memorial Hospitals in La Jolla and Encinitas, Calif., most recently as chairman, Department of Medicine. Dr. White serves as a member of the board of directors at Arena Pharmaceuticals, a clinical-stage biopharmaceutical company specializing in drugs for cardiovascular, central nervous system, inflammatory and metabolic diseases; and on the board of Marshall Edwards, Inc., an oncology company focused on the clinical development of novel anti-cancer therapeutics. She also serves as a member of the board of directors at Pharmacyclics, Inc, a pharmaceutical company developing products to treat cancer and other diseases. Dr. White holds a B.A. in Biology and an M.D. from the University of Chicago and is board certified in both Internal Medicine and Medical Oncology.
Geoffrey M. Parker
Geoffrey M. Parker has served on our board of directors since June 2010. Since July 2009, Mr. Parker has served in a consulting capacity as the chief business officer of InteKrin Therapeutics, a privately-held biopharmaceutical company in Los Altos, California, focused on developing and commercializing therapeutics for neuroendocrine, metabolic, and immune disorders and has served in a consulting capacity as an advisor to the chief executive officer of Anacor Pharmaceuticals since December 2009, a biopharmaceutical company developing novel small-molecule therapeutics. From 1997 to April 2009, Mr. Parker was a vice president, then managing director and finally partner at the global investment banking and securities firm Goldman Sachs Group, Inc., leading their West Coast Healthcare Investment Banking practice during this time. Mr. Parker also served in various capacities with Goldman Sachs Group, Inc. from 1990 to 1995 and 1986 to 1988. From 1995 to 1997, Mr. Parker was vice president at Feibusch & Co., a venture capital firm in Larkspur, California. Mr. Parker is currently a member of the board of directors for ChemoCentryx, Inc., a clinical stage privately-held biopharmaceutical company. Mr. Parker received an A.B. from Dartmouth College in engineering sciences and economics and an M.B.A. from Stanford University.